Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 2Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

ivosidenib 1Magnesium 114-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × AML × Clear all
NCT06717958 2025-07-02

PIVOT

Technische Universität Dresden

Phase 2 Recruiting
76 enrolled

AML

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting
72 enrolled

AML

NCT03275636 2024-08-07

HAMLET

DKMS gemeinnützige GmbH

Phase 2/3 Completed
98 enrolled

AML

NCT05252572 2022-02-23

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Unknown
36 enrolled

AML

NCT05239689 2022-02-15

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Unknown
36 enrolled

AML

NCT02418000 2019-03-20

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Spirita Oncology, LLC

Phase 1/2 Terminated
27 enrolled 32 charts

AML

Data powered by HemOnc (CC BY 4.0) Colophon âš¡